BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025
Reuters
Sep 22
BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025
BridgeBio Pharma, Inc. has announced that it will present additional data on the cardiovascular outcomes of Acoramidis from the ATTRibute-CM study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The event will take place in Minneapolis, MN from September 26 - 29, 2025. The presentations will include one late-breaking clinical trials oral presentation by Dr. Ahmad Masri, focusing on the effect of Acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM, scheduled for September 28. Additionally, Dr. Lily Stern will deliver an oral presentation on September 27, highlighting the reduction in risk of all-cause mortality and cardiovascular-related hospitalization with continuous Acoramidis treatment. Several poster sessions are also planned, including the mitigation of NT-proBNP level rises by Acoramidis, presented by Dr. Nitasha Sarswat. These presentations aim to provide further insights into the efficacy and safety of Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9532587-en) on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.